Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation
- 14 October 2014
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 94 (3) , 375-378
Abstract
Acute myeloid leukemia (AML) relapse is often associated with a poor outcome, especially after allogeneic stem cell transplantation (Allo-SCT). In patients relapsing early after SCT treatment, options are further limited by the fear for increased toxicity. We report our experience with ARA-C and gemtuzumab ozogamicin (GO) combination in relapsed post-SCT AML patients. Therapy consisted of ARA-C (1 gr/m2) for 4 days followed by one dose of GO 9 mg/m2 on day 5 and was supported by donor stem cells when possible. Responding patients not developing graft versus host disease (GVHD) were eligible for immunotherapy with donor lymphocyte infusion (DLI) or a second Allo-SCT. Sixteen patients, median age 53 years (range 31–63), are included in this analysis. Patients underwent SCT for high-risk AML (n = 11) or AML relapse (n = 5), and 81 % had an early post-SCT relapse. Responses were achieved in 60 % of evaluable patients (CR-5 CRp-4). Median probabilities of survival (OS) and event-free survival (EFS) in the entire cohort, responding and non-responding patients were 103 and 76 days, 183 and 97 days, and 79 and 16 days, respectively. At 1-year follow-up, 25 % of patients were alive; however, all had relapse. Treatment resulted in grade 3–4 neutropenia and thrombocytopenia in all patients, and 27 % each had grade 3–4 hyperbilirubinemia or elevation of liver enzymes. One patient died during treatment due to intracranial hemorrhage. Of the six patients proceeding to second SCT or receiving DLI, three patients developed mild veno-occlusive disease (VOD). Combination therapy with ARA-C and GO after SCT results in short-term disease control and limited toxicity and could be considered for patients who are candidates for further immunotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Salvage therapy for relapsed or refractory acute myeloid leukemiaTherapeutic Advances in Hematology, 2011
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Leukemia Research, 2011
- Advantage of MIDAM Protocol in Treatment of Elderly Patients With Refractory and Relapsing Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2008
- Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantBone Marrow Transplantation, 2008
- Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusionLeukemia, 2007
- Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantationBone Marrow Transplantation, 2007
- Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplantNature Clinical Practice Oncology, 2007
- Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplantBone Marrow Transplantation, 2004
- Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseBone Marrow Transplantation, 2002